Thông tin thuốc gốc
Chỉ định và Liều dùng
Type 2 diabetes mellitus
Adult: As immediate-release: Initially, 2.5-5 mg daily as a single dose. Adjust dose at intervals of several days in increments of 2.5-5 mg daily according to response. Doses >15 mg may be given in 2 divided doses. Max: 20 mg daily. As extended-release: Initially, 2.5-5 mg once daily, adjust dose according to response in increments of 5-10 mg once weekly. Max: 20 mg
Elderly: Initially, 2.5 mg once daily, titrate dose by 2.5-5 mg daily at 1-2 weeks intervals. Maintenance dosing should be conservative.
Suy thận
Mild to moderate: As immediate release: Initially, 2.5 mg once daily, then elective titration up to 20 mg daily. Maintenance dosing should be conservative. As extended-release: 2.5 mg once daily. Severe: Contraindicated.
Suy gan
Mild to moderate: Initially, 2.5 mg once daily. Maintenance dosing should be conservative. Severe: Contraindicated.
Cách dùng
immediate-release: Should be taken on an empty stomach. Take 30 min before meals.
extended-release: Should be taken with food. Swallow whole, do not chew/crush/divide.
Chống chỉ định
Hypersensitivity to glipizide, other sulfonylureas or sulfonamides. Type 1 diabetes mellitus, diabetic ketoacidosis with or without coma or history of ketoacidotic coma, severe thyroid impairment. Severe renal or hepatic impairment. Pre-existing pathologic or iatrogenic severe gastrointestinal narrowing (extended-release). Concomitant use with miconazole.
Thận trọng
Patients with established atherosclerotic CV disease, prior allergic reactions to sulphonamides, G6PD deficiency, stress-related states. Mild to moderate renal and hepatic impairment. Elderly, debilitated and malnourished patients. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypoglycaemia, hypersensitivity reactions, sulfonylurea-induced haemolytic anaemia (in G6PD deficiency).
Blood and lymphatic system disorders: Leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, pancytopenia.
Eye disorders: Blurred vision.
Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting, gastralgia.
Hepatobiliary disorders: Cholestatic jaundice, hepatic porphyria.
Metabolism and nutrition disorders: Disulfiram-like reactions.
Nervous system disorders: Dizziness, drowsiness, somnolence, tremor, headache.
Skin and subcutaneous tissue disorders: Eczema, erythema morbilliform, maculopapular eruptions, urticaria, pruritus.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, drowsiness, and visual disturbances, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor blood and urine glucose concentrations, glycosylated Hb, renal function, LFT, weight; signs and symptoms of hypoglycaemia.
Quá liều
Symptoms: Hypoglycaemia; faintness, confusion, sweating or shaking. Management: Mild hypoglycaemia may be treated with oral glucose or with any sugary food or drinks. For severe hypoglycaemia, administer glucagon or rapid IV inj of glucose 50% solution followed by continuous infusion of glucose 10% solution. Monitor patient for at least 48 hours.
Tương tác
Increased plasma concentration with fluconazole and voriconazole. Increased hypoglycaemic effect with NSAIDs (e.g. phenylbutazone), ACE inhibitors, MAOIs, cimetidine, chloramphenicol, probenecid, coumarins and fibrates.
Potentially Fatal: Severe hypoglycaemia leading to coma with miconazole.
Tương tác với thức ăn
Increased hypoglycaemic action with alcohol.
Tác dụng
Description: Glipizide stimulates insulin release from pancreatic ß-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
Duration: 12-24 hours.
Absorption: Rapidly and completely absorbed from the gastrointestinal tract (immediate-release). Food delays absorption. Bioavailability: 90-100%. Time to peak plasma concentration: 1-3 hours; 6-12 hours (extended-release).
Distribution: Plasma protein binding: 98-99%, primarily to albumin. Volume of distribution: 10-11 L.
Metabolism: Metabolised in the liver by CYP2C19 to inactive metabolites.
Excretion: Via urine (<10% as unchanged drug; 80% as metabolites); faeces (10%). Elimination half-life: 2-5 hours.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Glipizide, CID=3478, (accessed on Jan. 22, 2020)

Bảo quản
Immediate-release: Store below 25°C. Protect from light. Extended-release: Store between 20-25°C. Protect from moisture and humidity.
Phân loại MIMS
Thuốc trị đái tháo đường
Phân loại ATC
A10BB07 - glipizide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Glipizide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 15/05/2019.

Buckingham R (ed). Glipizide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 15/05/2019.

Glipizide Tablet (Sandoz Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/05/2019.

Glipizide Tablet, Extended Release (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/05/2019.

Glucotrol and Glucotrol XL Tablets. U.S. FDA. Accessed 28/08/2014.

Joint Formulary Committee. Glipizide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 15/05/2019.

McEvoy GK, Snow EK, Miller J et al (eds). Glipizide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 28/08/2014.

Minidiab Tablet [Pfizer (Malaysia) Sdn. Bhd.]. National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 15/05/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Glipizide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Glibenese
  • Glipizid DOMESCO
  • Glipizide-AQP
  • Glupin CR
  • Glynase
  • Minidiab
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in